Carlos López

机构：University of Kentucky, Universidad Autónoma del Estado de México, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Ministerio de Salud Pública, Universidad Nacional Autónoma de México · ORCID：0000-0002-8901-741X

发表论文 315 篇 · 总被引 12057 次 · h-index 45

代表论文

• Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) (2025 · Clinical Cancer Research · 被引 6)
• Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry (2025 · The Journal of Clinical Endocrinology & Metabolism · 被引 5)
• Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) (2025 · 被引 1)
• 6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1 (2025 · Annals of Oncology · 被引 1)
• Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study (2026 · ESMO Open)
• Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial (2026 · Liver Cancer)